Prediction of immune-related adverse events in urological cancer during checkpoint inhibitor immunotherapy through immunohistochemical analysis of tumorous LCP1/ADPGK
Liqing Xu, Xi Zhang, Zihao Tao, Yiceng Ying, Xueqin Zeng, Kaiwei Yang, Yang Wang, Ninghan Feng, Xuesong Li, Yaqian Li, Qi Tang · 2026
Read Prediction of immune-related adverse events in urological cancer during checkpoint inhibitor immunotherapy through immunohistochemical analysis of tumorous LCP1/ADPGK by Liqing Xu, Xi Zhang, Zihao Tao, Yiceng Ying, Xueqin Zeng, Kaiwei Yang, Yang Wang, Ninghan Feng, Xuesong Li, Yaqian Li, Qi Tang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13266032.txt.
Description
Liqing Xu and colleagues test two tumour proteins as predictors of immune side effects during cancer immunotherapy, in a 2026 study. Checkpoint drugs have transformed urological cancer care, yet immune side effects can halt treatment. Tumour staining for LCP1 and ADPGK was assessed. Blood measures served as the conventional comparison.
Each protein alone predicted side effects with good accuracy. A combined model performed better still, across cancer subtypes. Accuracy held across different timings of side effect onset. Both markers beat standard blood parameters. The authors propose staining-guided dosing to personalise treatment and reduce forced discontinuation.
Catalog record
| CREATOR | Liqing Xu, Xi Zhang, Zihao Tao, Yiceng Ying, Xueqin Zeng, Kaiwei Yang, Yang Wang, Ninghan Feng, Xuesong Li, Yaqian Li, Qi Tang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |